These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34148055)

  • 1. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
    Pepper AGS; Zucchetto A; Norris K; Tissino E; Polesel J; Soe Z; Allsup D; Hockaday A; Ow PL; Hillmen P; Rawstron A; Catovsky D; Bulian P; Bomben R; Baird DM; Fegan CD; Gattei V; Pepper C
    Leukemia; 2022 Jan; 36(1):271-274. PubMed ID: 34148055
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
    Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
    Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
    Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
    Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
    Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomere length predicts for outcome to FCR chemotherapy in CLL.
    Norris K; Hillmen P; Rawstron A; Hills R; Baird DM; Fegan CD; Pepper C
    Leukemia; 2019 Aug; 33(8):1953-1963. PubMed ID: 30700843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCR achieves long-term durable remissions in patients with
    Chai-Adisaksopha C; Brown JR
    Blood; 2017 Nov; 130(21):2278-2282. PubMed ID: 29025740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
    Jain P; Nogueras González GM; Kanagal-Shamanna R; Rozovski U; Sarwari N; Tam C; Wierda WG; Thompson PA; Jain N; Luthra R; Quesada A; Sanchez-Petitto G; Ferrajoli A; Burger J; Kantarjian H; Cortes J; O'Brien S; Keating MJ; Estrov Z
    Br J Haematol; 2018 Jan; 180(1):33-40. PubMed ID: 29164608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
    Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
    Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
    Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
    Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
    Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
    Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
    Xu M; Fan L; Miao KR; Liu P; Xu W; Li JY
    Med Oncol; 2012 Sep; 29(3):2102-10. PubMed ID: 21881978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
    Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
    Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
    Delgado J; Salaverria I; Baumann T; Martínez-Trillos A; Lee E; Jiménez L; Navarro A; Royo C; Santacruz R; López C; Payer AR; Colado E; González M; Armengol L; Colomer D; Pinyol M; Villamor N; Aymerich M; Carrió A; Costa D; Clot G; Giné E; López-Guillermo A; Campo E; Beà S
    Haematologica; 2014 Nov; 99(11):e231-4. PubMed ID: 24997154
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
    Lanasa MC; Davis PH; Datto M; Li Z; Gockerman JP; Moore JO; DeCastro CM; Friedman DR; Diehl LF; Rehder C; Cook H; Daugherty FJ; Matta KM; Weinberg JB; Rizzieri D
    Leuk Lymphoma; 2012 Feb; 53(2):218-24. PubMed ID: 21827374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.
    Šimkovič M; Vodárek P; Motyčková M; Écsiová D; Rozsívalová P; Móciková H; Štěpánková P; Sýkorová A; Hrochová K; Vrbacký F; Belada D; Žák P; Smolej L
    Eur J Clin Invest; 2021 Apr; 51(4):e13421. PubMed ID: 33022756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Hotinski AK; Best OG; Thurgood LA; Lower KM; Kuss BJ
    Br J Haematol; 2021 Feb; 192(3):e77-e81. PubMed ID: 33278845
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
    Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
    Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.